MGC Derma launches new CBD-infused skincare product
Published 10-MAY-2018 12:14 P.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
MGC Pharmaceutical's (ASX:MXC) Derma division today launched a new skincare product in its Derma Plus collection — the CBD Herbal Replenish Cream, which is specifically developed for external skincare and relief from inflammatory skin conditions.
This latest piece of news follows on from the successful January launch of the CBD Herbal Repair Cream, which is formulated to treat dry, sensitive and flaky skin.
MGC Derma expects to launch a third Derma Plus product, the CBD Herbal Balm for oily and acne-prone skin, later this year.
Products in the Derma Plus range are dermatologically tested, research backed, and designed to improve the skin’s natural defence and to stimulate skin functions and regeneration. These products have been formulated with propriety CBD compounds extracted from the cannabis plant, produced by the MGC Botanic division. These products are available to MGC Derma’s base of global customers, and are for sale in regions where CBD-based products are permitted.
Encouragingly, an independent dermatological study in Europe last year found that these compounds deliver strong improvements across a range of skin conditions, including dry skin (71 per cent improvement), flaking skin (65 per cent improvement), and itching skin (86 per cent improvement).
With these kinds of positive testing results, 92 per cent of patients said they would continue using the cream.
Of course, as always, success is not guaranteed — consider your own personal circumstances before investing, and seek professional financial advice.
Co-founder, executive director and CEO, Roby Zomer, said that he was proud of the progress of MXC’s MGC Derma cosmetics subsidiary.
“MGC Derma Plus is a premium range designed to support the capacity for skin repair and prevent skin problems,” Zomer said. “The newest product will be a valuable addition to the range supporting our brand and increasing our presence within the CBD infused skincare space.”
This latest development comes hot on the heels of a recent string of good news from MXC. In April, the company unveiled its contract with the Maltese government to construct a state-of-the-art medical cannabis production and cultivation facility spanning 4,000 square metres. This makes MXC one of only five companies — and the only company in Australia — to be awarded a full medical cannabis production and cultivation contract.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
